|
1
|
Blechacz B and Gores GJ:
Cholangiocarcinoma: Advances in pathogenesis, diagnosis, and
treatment. Hepatology. 48:308–321. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Welzel TM, McGlynn KA, Hsing AW, O'Brien
TR and Pfeiffer RM: Impact of classification of hilar
cholangiocarcinomas (Klatskin tumors) on the incidence of intra-
and extrahepatic cholangiocarcinoma in the United States. J Natl
Cancer Inst. 98:873–875. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Everhart JE and Ruhl CE: Burden of
digestive diseases in the United States Part III: Liver, biliary
tract, and pancreas. Gastroenterology. 136:1134–1144. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tyson GL and El-Serag HB: Risk factors for
cholangiocarcinoma. Hepatology. 54:173–184. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kozako T, Soeda S, Yoshimitsu M, Arima N,
Kuroki A, Hirata S, Tanaka H, Imakyure O, Tone N, Honda S, et al:
Angiotensin II type 1 receptor blocker telmisartan induces
apoptosis and autophagy in adult T-cell leukemia cells. FEBS Open
Bio. 6:442–460. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Koyama N, Nishida Y, Ishii T, Yoshida T,
Furukawa Y and Narahara H: Telmisartan induces growth inhibition,
DNA double-strand breaks and apoptosis in human endometrial cancer
cells. PLoS One. 9:e930502014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Okazaki M, Fushida S, Harada S, Tsukada T,
Kinoshita J, Oyama K, Tajima H, Ninomiya I, Fujimura T and Ohta T:
The angiotensin II type 1 receptor blocker candesartan suppresses
proliferation and fibrosis in gastric cancer. Cancer Lett.
355:46–53. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Funao K, Matsuyama M, Kawahito Y, Sano H,
Chargui J, Touraine JL, Nakatani T and Yoshimura R: Telmisartan is
a potent target for prevention and treatment in human prostate
cancer. Oncol Rep. 20:295–300. 2008.PubMed/NCBI
|
|
9
|
Funao K, Matsuyama M, Kawahito Y, Sano H,
Chargui J, Touraine JL, Nakatani T and Yoshimura R: Telmisartan as
a peroxisome proliferator-activated receptor-γ ligand is a new
target in the treatment of human renal cell carcinoma. Mol Med Rep.
2:193–198. 2009.PubMed/NCBI
|
|
10
|
Lee LD, Mafura B, Lauscher JC, Seeliger H,
Kreis ME and Gröne J: Antiproliferative and apoptotic effects of
telmisartan in human colon cancer cells. Oncol Lett. 8:2681–2686.
2014.PubMed/NCBI
|
|
11
|
Fujihara S, Morishita A, Ogawa K, Tadokoro
T, Chiyo T, Kato K, Kobara H, Mori H, Iwama H and Masaki T: The
angiotensin II type 1 receptor antagonist telmisartan inhibits cell
proliferation and tumor growth of esophageal adenocarcinoma via the
AMPKα/mTOR pathway in vitro and in vivo. Oncotarget. 8:8536–8549.
2017.PubMed/NCBI
|
|
12
|
Briggs CD, Neal CP, Mann CD, Steward WP,
Manson MM and Berry DP: Prognostic molecular markers in
cholangiocarcinoma: A systematic review. Eur J Cancer. 45:33–47.
2009. View Article : Google Scholar
|
|
13
|
Sharma PS, Sharma R and Tyagi R:
Inhibitors of cyclin dependent kinases: Useful targets for cancer
treatment. Curr Cancer Drug Targets. 8:53–75. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Baldin V, Lukas J, Marcote MJ, Pagano M
and Draetta G: Cyclin D1 is a nuclear protein required for cell
cycle progression in G1. Genes Dev. 7:812–821. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kato K, Gong J, Iwama H, Kitanaka A, Tani
J, Miyoshi H, Nomura K, Mimura S, Kobayashi M, Aritomo Y, et al:
The anti-diabetic drug metformin inhibits gastric cancer cell
proliferation in vitro and in vivo. Mol Cancer Ther. 11:549–560.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hui AM, Cui X, Makuuchi M, Li X, Shi YZ
and Takayama T: Decreased p27(Kip1) expression and cyclin D1
overexpression, alone and in combination, influence recurrence and
survival of patients with resectable extrahepatic bile duct
carcinoma. Hepatology. 30:1167–1173. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kobayashi K, Morishita A, Iwama H, Fujita
K, Okura R, Fujihara S, Yamashita T, Fujimori T, Kato K, Kamada H,
et al: Galectin-9 suppresses cholangiocarcinoma cell proliferation
by inducing apoptosis but not cell cycle arrest. Oncol Rep.
34:1761–1770. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tadokoro T, Morishita A, Fujihara S, Iwama
H, Niki T, Fujita K, Akashi E, Mimura S, Oura K, Sakamoto T, et al:
Galectin-9: An anticancer molecule for gallbladder carcinoma. Int J
Oncol. 48:1165–1174. 2016.PubMed/NCBI
|
|
19
|
Fujita K, Iwama H, Sakamoto T, Okura R,
Kobayashi K, Takano J, Katsura A, Tatsuta M, Maeda E, Mimura S, et
al: Galectin-9 suppresses the growth of hepatocellular carcinoma
via apoptosis in vitro and in vivo. Int J Oncol. 46:2419–2430.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schutte B, Henfling M, Kölgen W, Bouman M,
Meex S, Leers MP, Nap M, Björklund V, Björklund P, Björklund B, et
al: Keratin 8/18 breakdown and reorganization during apoptosis. Exp
Cell Res. 297:11–26. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
D'Incalci M, Colombo T, Ubezio P,
Nicoletti I, Giavazzi R, Erba E, Ferrarese L, Meco D, Riccardi R,
Sessa C, et al: The combination of yondelis and cisplatin is
synergistic against human tumor xenografts. Eur J Cancer.
39:1920–1926. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Masaki T, Shiratori Y, Rengifo W, Igarashi
K, Yamagata M, Kurokohchi K, Uchida N, Miyauchi Y, Yoshiji H,
Watanabe S, et al: Cyclins and cyclin-dependent kinases:
Comparative study of hepatocellular carcinoma versus cirrhosis.
Hepatology. 37:534–543. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Masaki T, Shiratori Y, Rengifo W, Igarashi
K, Matsumoto K, Nishioka M, Hatanaka Y and Omata M: Hepatocellular
carcinoma cell cycle: Study of Long-Evans cinnamon rats.
Hepatology. 32:711–720. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Igarashi K, Masaki T, Shiratori Y, Rengifo
W, Nagata T, Hara K, Oka T, Nakajima J, Hisada T and Hata E:
Activation of cyclin D1-related kinase in human lung
adenocarcinoma. Br J Cancer. 81:705–711. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Itabashi H, Maesawa C, Oikawa H, Kotani K,
Sakurai E, Kato K, Komatsu H, Nitta H, Kawamura H, Wakabayashi G,
et al: Angiotensin II and epidermal growth factor receptor
cross-talk mediated by a disintegrin and metalloprotease
accelerates tumor cell proliferation of hepatocellular carcinoma
cell lines. Hepatol Res. 38:601–613. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Molina Wolgien MC, Guerreiro da Silva ID,
Pinto Nazário AC, Nakaie CR, Correa-Noronha SA, Ribeiro de Noronha
SM and Facina G: Genetic association study of angiotensin II
receptor types 1 (A168G) and 2 (T1247G and A5235G) polymorphisms in
breast carcinoma among Brazilian women. Breast Care (Basel).
9:176–181. 2014. View Article : Google Scholar
|
|
27
|
Miyajima A, Kosaka T, Asano T, Asano T,
Seta K, Kawai T and Hayakawa M: Angiotensin II type I antagonist
prevents pulmonary metastasis of murine renal cancer by inhibiting
tumor angiogenesis. Cancer Res. 62:4176–4179. 2002.PubMed/NCBI
|
|
28
|
Sipahi I, Debanne SM, Rowland DY, Simon DI
and Fang JC: Angiotensin-receptor blockade and risk of cancer:
Meta-analysis of randomised controlled trials. Lancet Oncol.
11:627–636. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bhaskaran K, Douglas I, Evans S, van Staa
T and Smeeth L: Angiotensin receptor blockers and risk of cancer:
Cohort study among people receiving antihypertensive drugs in UK
General Practice Research Database. BMJ. 344:e26972012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Makar GA, Holmes JH and Yang YX:
Angiotensin-converting enzyme inhibitor therapy and colorectal
cancer risk. J Natl Cancer Inst. 106:djt3742014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kinoshita J, Fushida S, Harada S, Yagi Y,
Fujita H, Kinami S, Ninomiya I, Fujimura T, Kayahara M, Yashiro M,
et al: Local angiotensin II-generation in human gastric cancer:
Correlation with tumor progression through the activation of
ERK1/2, NF-κB and survivin. Int J Oncol. 34:1573–1582. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Okamoto K, Tajima H, Ohta T, Nakanuma S,
Hayashi H, Nakagawara H, Onishi I, Takamura H, Ninomiya I, Kitagawa
H, et al: Angiotensin II induces tumor progression and fibrosis in
intrahepatic cholangiocarcinoma through an interaction with hepatic
stellate cells. Int J Oncol. 37:1251–1259. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Du N, Feng J, Hu LJ, Sun X, Sun HB, Zhao
Y, Yang YP and Ren H: Angiotensin II receptor type 1 blockers
suppress the cell proliferation effects of angiotensin II in breast
cancer cells by inhibiting AT1R signaling. Oncol Rep. 27:1893–1903.
2012.PubMed/NCBI
|
|
34
|
Matsuda Y: Molecular mechanism underlying
the functional loss of cyclin dependent kinase inhibitors p16 and
p27 in hepatocellular carcinoma. World J Gastroenterol.
14:1734–1740. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Benson SC, Pershadsingh HA, Ho CI,
Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA and
Kurtz TW: Identification of telmisartan as a unique angiotensin II
receptor antagonist with selective PPARgamma-modulating activity.
Hypertension. 43:993–1002. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Stangier J, Su CA and Roth W:
Pharmacokinetics of orally and intravenously administered
telmisartan in healthy young and elderly volunteers and in
hypertensive patients. J Int Med Res. 28:149–167. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Scalera F, Martens-Lobenhoffer J, Bukowska
A, Lendeckel U, Täger M and Bode-Böger SM: Effect of telmisartan on
nitric oxide - asymmetrical dimethylarginine system: Role of
angiotensin II type 1 receptor gamma and peroxisome proliferator
activated receptor gamma signaling during endothelial aging.
Hypertension. 51:696–703. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sukumaran S, Patel HJ and Patel BM:
Evaluation of role of telmisartan in combination with
5-fluorouracil in gastric cancer cachexia. Life Sci. 154:15–23.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Perry JE, Grossmann ME and Tindall DJ:
Epidermal growth factor induces cyclin D1 in a human prostate
cancer cell line. Prostate. 35:117–124. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Herbst RS and Shin DM: Monoclonal
antibodies to target epidermal growth factor receptor-positive
tumors: A new paradigm for cancer therapy. Cancer. 94:1593–1611.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Masaki T, Hatanaka Y, Nishioka M, Tokuda
M, Shiratori Y, Reginfo W and Omata M: Activation of epidermal
growth factor receptor kinase in gastric carcinoma: A preliminary
study. Am J Gastroenterol. 95:2135–2136. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Han W and Lo HW: Landscape of EGFR
signaling network in human cancers: Biology and therapeutic
response in relation to receptor subcellular locations. Cancer
Lett. 318:124–134. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Geynisman DM and Catenacci DV: Toward
personalized treatment of advanced biliary tract cancers. Discov
Med. 14:41–57. 2012.PubMed/NCBI
|
|
44
|
Jo Chae K, Rha SY, Oh BK, Koo JS, Kim YJ,
Choi J, Park C and Park YN: Expression of matrix
metalloproteinase-2 and -9 and tissue inhibitor of
metalloproteinase-1 and -2 in intraductal and nonintraductal growth
type of cholangiocarcinoma. Am J Gastroenterol. 99:68–75. 2004.
View Article : Google Scholar
|
|
45
|
Meng F, Henson R, Lang M, Wehbe H,
Maheshwari S, Mendell JT, Jiang J, Schmittgen TD and Patel T:
Involvement of human micro-RNA in growth and response to
chemotherapy in human cholangiocarcinoma cell lines.
Gastroenterology. 130:2113–2129. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Morishita A and Masaki T: miRNA in
hepatocellular carcinoma. Hepatol Res. 45:128–141. 2015. View Article : Google Scholar
|
|
47
|
Akao Y, Nakagawa Y and Naoe T: let-7
microRNA functions as a potential growth suppressor in human colon
cancer cells. Biol Pharm Bull. 29:903–906. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhu XM, Wu LJ, Xu J, Yang R and Wu FS:
Let-7c microRNA expression and clinical significance in
hepatocellular carcinoma. J Int Med Res. 39:2323–2329. 2011.
View Article : Google Scholar
|
|
49
|
Takamizawa J, Konishi H, Yanagisawa K,
Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y,
et al: Reduced expression of the let-7 microRNAs in human lung
cancers in association with shortened postoperative survival.
Cancer Res. 64:3753–3756. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong
C, Huang Y, Hu X, Su F, Lieberman J, et al: let-7 regulates self
renewal and tumorigenicity of breast cancer cells. Cell.
131:1109–1123. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lee YS and Dutta A: The tumor suppressor
microRNA let-7 represses the HMGA2 oncogene. Genes Dev.
21:1025–1030. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Johnson SM, Grosshans H, Shingara J, Byrom
M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D and Slack
FJ: RAS is regulated by the let-7 microRNA family. Cell.
120:635–647. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Osada H and Takahashi T: let-7 and
miR-17-92: Small-sized major players in lung cancer development.
Cancer Sci. 102:9–17. 2011. View Article : Google Scholar
|
|
54
|
Sun H, Ding C, Zhang H and Gao J: Let-7
miRNAs sensitize breast cancer stem cells to radiation-induced
repression through inhibition of the cyclin D1/Akt1/Wnt1 signaling
pathway. Mol Med Rep. 14:3285–3292. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Lin MS, Chen WC, Huang JX, Gao HJ and
Sheng HH: Aberrant expression of microRNAs in serum may identify
individuals with pancreatic cancer. Int J Clin Exp Med.
7:5226–5234. 2014.
|
|
56
|
Cui ZH, Shen SQ, Chen ZB and Hu C: Growth
inhibition of hepatocellular carcinoma tumor endothelial cells by
miR-204-3p and underlying mechanism. World J Gastroenterol.
20:5493–5504. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Li W, Shen S, Wu S, Chen Z, Hu C and Yan
R: Regulation of tumorigenesis and metastasis of hepatocellular
carcinoma tumor endothelial cells by microRNA-3178 and underlying
mechanism. Biochem Biophys Res Commun. 464:881–887. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Ueda T, Volinia S, Okumura H, Shimizu M,
Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, et al:
Relation between microRNA expression and progression and prognosis
of gastric cancer: A microRNA expression analysis. Lancet Oncol.
11:136–146. 2010. View Article : Google Scholar
|
|
59
|
Sun L, Jiang R, Li J, Wang B, Ma C, Lv Y
and Mu N: MicoRNA-425-5p is a potential prognostic biomarker for
cervical cancer. Ann Clin Biochem. 54:127–133. 2017. View Article : Google Scholar
|
|
60
|
Di Leva C, Piovan C, Gasparini P, Ngankeu
A, Taccioli C, Briskin D, Cheung DG, Bolon B, Anderlucci L, Alder
H, et al: Estrogen mediated-activation of miR-191/425 cluster
modulates tumorigenicity of breast cancer cells depending on
estrogen receptor status. PLoS Genet. 9:e10033112013. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Yu M, Trobridge P, Wang Y, Kanngurn S,
Morris SM, Knoblaugh S and Grady WM: Inactivation of TGF-β
signaling and loss of PTEN cooperate to induce colon cancer in
vivo. Oncogene. 33:1538–1547. 2014. View Article : Google Scholar
|
|
62
|
Ma J, Liu J, Wang Z, Gu X, Fan Y, Zhang W,
Xu L, Zhang J and Cai D: NF-kappaB-dependent microRNA-425
upregulation promotes gastric cancer cell growth by targeting PTEN
upon IL-1β induction. Mol Cancer. 13:402014. View Article : Google Scholar
|
|
63
|
Yang Y-F, Wang F, Xiao J-J, Song Y, Zhao
YY, Cao Y, Bei YH and Yang CQ: MiR-222 overexpression promotes
proliferation of human hepatocellular carcinoma HepG2 cells by
downregulating p27. Int J Clin Exp Med. 7:893–902. 2014.PubMed/NCBI
|
|
64
|
Sun C, Li N, Zhou B, Yang Z, Ding D, Weng
D, Meng L, Wang S, Zhou J, Ma D, et al: miR-222 is upregulated in
epithelial ovarian cancer and promotes cell proliferation by
downregulating p27kip1. Oncol Lett. 6:507–512.
2013.PubMed/NCBI
|
|
65
|
Saito Y, Suzuki H, Matsuura M, Sato A,
Kasai Y, Yamada K, Saito H and Hibi T: MicroRNAs in hepatobiliary
and pancreatic cancers. Front Genet. 2:662011. View Article : Google Scholar
|
|
66
|
Zhang C-Z, Han L, Zhang A-L, Fu Y-C, Yue
X, Wang G-X, Jia Z-F, Pu P-Y, Zhang Q-Y and Kang C-S: MicroRNA-221
and microRNA-222 regulate gastric carcinoma cell proliferation and
radioresistance by targeting PTEN. BMC Cancer. 10:3672010.
View Article : Google Scholar
|
|
67
|
Visone R, Russo L, Pallante P, De Martino
I, Ferraro A, Leone V, Borbone E, Petrocca F, Alder H, Croce CM, et
al: MicroRNAs (miR)-221 and miR-222, both overexpressed in human
thyroid papillary carcinomas, regulate p27Kip1 protein levels and
cell cycle. Endocr Relat Cancer. 14:791–798. 2007. View Article : Google Scholar : PubMed/NCBI
|
